Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT05745415
Other study ID # 4-2017-1161
Secondary ID
Status Completed
Phase
First received
Last updated
Start date March 29, 2018
Est. completion date March 29, 2021

Study information

Verified date February 2023
Source Yonsei University
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

The treatment performance of pancreatic cancer has not changed significantly over the past 20 years and is still less than 10%. In addition, 80-90% of pancreatic cancer patients are found to be already advanced at the time of diagnosis, and it is the best malignant tumor in the human body with a 5-year survival rate of less than 10% and a median survival period of less than 1 year. However, early diagnosis of pancreatic cancer is still difficult, and there is no effective treatment other than surgery, so the increase in long-term survival rate over the past 20 years has been insignificant or stagnant. The response rate to anticancer drug treatment after surgery or anticancer drug when surgery is not possible is only around 20%, so it is very urgent to discover new biomarkers in predicting drug resistance and recurrence after surgery and predicting prognosis in advance. Minimally non-invasive diagnostic techniques are very important to detect and track cancer progression in the clinic. In particular, histological diagnosis and analysis have limitations in carcinomas, such as pancreatic cancer, which are small and distant, making it difficult to obtain tissue samples. CA 19-9, a prognostic marker for existing pancreatic cancer, 1) has low specificity for early diagnosis of pancreas, 2) is not detected in lewis A, B antibody-negative patients, and 3) shows false positive in cases with cholangitis at the same time. Because it has many disadvantages, the development of prognostic biomarkers in blood is urgently needed. Recently, a study has been reported that the presence or absence of detection of circulating tumor cells is directly related to the prognosis of pancreatic cancer patients, and can be used for monitoring the patient's treatment response and for recurrence after surgery. In particular, the process of cancer metastasis consists of epithelial-to-mesenchymal transition and migration of cancer cells into the blood, and the existence of cancer stem cells is very important for metastasis and drug treatment resistance. Eventually, it is known to cause pancreatic cancer metastasis and recurrence. Cancer stem cells have the ability to self-renew, the capability of developing, multiple cell lineages, and the potential of extensive proliferation, and the ability to detect cancer stem cells in the blood is important in pancreatic cancer patients who are at high risk of metastasis and recurrence. It is a non-invasive screening tool. Comparatively evaluate the treatment response and prognosis of pancreatic cancer patients according to the characteristics and subtypes of circulating cancer cells.


Recruitment information / eligibility

Status Completed
Enrollment 40
Est. completion date March 29, 2021
Est. primary completion date March 29, 2021
Accepts healthy volunteers No
Gender All
Age group 20 Years and older
Eligibility Inclusion Criteria: - Men and women over 20 years of age - Patients diagnosed with pancreatic cancer histologically or radiologically Exclusion Criteria: - non-pancreatic cancer - Patients who failed to obtain informed consent from the patient

Study Design


Related Conditions & MeSH terms


Locations

Country Name City State
Korea, Republic of Yonsei University Health System, Severance Hospital Seoul

Sponsors (1)

Lead Sponsor Collaborator
Yonsei University

Country where clinical trial is conducted

Korea, Republic of, 

Outcome

Type Measure Description Time frame Safety issue
Primary Progression free survival Progression free survival : The length of time during and after the treatment of a disease, such as cancer, that a patient lives with the disease but it does not get worse the duration from treatment initiation to disease progression (Up to 100 weeks)
Secondary Overall survival Overall survival : The length of time from either the date of diagnosis or the start of treatment for a disease, such as cancer, that patients diagnosed with the disease are still alive. he duration from diagnosis of pancreatic cancer to death or last follow-up (up to 100 weeks)
See also
  Status Clinical Trial Phase
Completed NCT01354795 - Prospective Study Comparing Methods of Obtainment of Specimen After EUS-FNA in Patients With Peri-pancreatic Mass N/A
Completed NCT00958841 - Study of Pasireotide in Patients With Rare Tumors of Neuroendocrine Origin Phase 2
Terminated NCT00249301 - A Study of MLN8054 in Patients With Advanced Solid Tumors Phase 1
Recruiting NCT06122896 - Prospective Screening for Pancreatic Ductal Adenocarcinoma in High-Risk Individuals Early Phase 1
Terminated NCT02602067 - 131Iodine-Tenatumomab Treatment in Tenascin-C Positive Cancer Patients Phase 1
Recruiting NCT06411795 - Rectus Sheath Block With Liposomal Bupivacaine Versus Thoracic Epidural Analgesia for Pain Control Following Pancreatoduodenectomy Phase 2
Completed NCT03622229 - EUS-FNB for Solid Pancreatic Lesions: Side-fenestrated Vs Fork-tip Needle N/A
Recruiting NCT06400472 - A Study of LY4170156 in Participants With Selected Advanced Solid Tumors Phase 1
Completed NCT02791503 - CROSSFIRE Trial: Comparing the Efficacy of Irreversible Electroporation With Radiotherapy N/A
Recruiting NCT05786716 - DETERMINE Trial Treatment Arm 04: Trastuzumab in Combination With Pertuzumab in Adult, Teenage/Young Adult and Paediatric Patients With Cancers With HER2 Amplification or Activating Mutations Phase 2/Phase 3
Completed NCT03322592 - EUS-FNB With ROSE Vs. EUS-FNB Without ROSE N/A
Recruiting NCT05083247 - Preoperative mFOLFIRINOX (or Gem-Nab-P) +/- Isotoxic High-dose SBRT for Borderline Resectable Pancreatic Adenocarcinoma Phase 2
Completed NCT00436423 - A Phase Ⅱ Study of Gemcitabine Combination With TS-1 in Patient With Advanced or Recurred Pancreatic Cancer Phase 2
Completed NCT02900950 - Multicolour Versus Monocolour Specimens Inking After Pancreaticoduodenectomy for Periampullary Cancer N/A
Completed NCT00711191 - A Study On An Immunostimulant Antibody In Combination With Chemotherapy For Advanced Cancer Of The Pancreas Phase 1
Completed NCT00222898 - Cancer Detection in Pancreatic Cysts N/A
Completed NCT00034281 - Safety and Tolerability Study of TAK-165 in Subjects With Tumors Expressing HER2 Phase 1
Completed NCT00005926 - Gemcitabine, Herceptin and Radiation to Treat Cancer of the Pancreas Phase 2
Recruiting NCT04164017 - Impact of Suction in the EUS-guided Fine Needle Biopsy of Solid Pancreatic Lesions N/A
Recruiting NCT05687123 - Testing the Addition of Sunitinib Malate to Lutetium Lu 177 Dotatate (Lutathera) in Pancreatic Neuroendocrine Tumors Phase 1